Big Pharma CEOs get candid about pricing and M&A

If you’re the CEO of one of the biggest pharma companies in the world, there’s likely a lot on your mind. With U.S. drug pricing negotiations on the table and volatility still roiling the biotech markets, molehills can become mountains in the blink of an eye.